Novavax (NVAX) Receivables - Other: 2009-2025
Historic Receivables - Other for Novavax (NVAX) over the last 12 years, with Sep 2025 value amounting to $5.2 million.
- Novavax's Receivables - Other fell 16.13% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 16.13%. This contributed to the annual value of $5.4 million for FY2024, which is 50.00% down from last year.
- Per Novavax's latest filing, its Receivables - Other stood at $5.2 million for Q3 2025, which was down 1.89% from $5.3 million recorded in Q2 2025.
- In the past 5 years, Novavax's Receivables - Other registered a high of $68.0 million during Q3 2022, and its lowest value of $200,000 during Q1 2024.
- For the 3-year period, Novavax's Receivables - Other averaged around $17.9 million, with its median value being $6.1 million (2025).
- As far as peak fluctuations go, Novavax's Receivables - Other crashed by 99.53% in 2024, and later spiked by 2,950.00% in 2025.
- Over the past 5 years, Novavax's Receivables - Other (Quarterly) stood at $35.3 million in 2021, then decreased by 18.98% to $28.6 million in 2022, then plummeted by 62.24% to $10.8 million in 2023, then slumped by 50.00% to $5.4 million in 2024, then dropped by 16.13% to $5.2 million in 2025.
- Its Receivables - Other was $5.2 million in Q3 2025, compared to $5.3 million in Q2 2025 and $6.1 million in Q1 2025.